JP2006503875A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006503875A5 JP2006503875A5 JP2004542493A JP2004542493A JP2006503875A5 JP 2006503875 A5 JP2006503875 A5 JP 2006503875A5 JP 2004542493 A JP2004542493 A JP 2004542493A JP 2004542493 A JP2004542493 A JP 2004542493A JP 2006503875 A5 JP2006503875 A5 JP 2006503875A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- hal
- independently
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 18
- 150000003839 salts Chemical group 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 11
- 102000011040 TRPV Cation Channels Human genes 0.000 claims description 6
- 108010062740 TRPV Cation Channels Proteins 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 26
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 17
- 239000012458 free base Substances 0.000 claims 10
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 9
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 8
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical compound C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 7
- 230000004913 activation Effects 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 4
- 230000006806 disease prevention Effects 0.000 claims 3
- 125000001246 bromo group Chemical group Br* 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000002346 iodo group Chemical group I* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- SWXXKWPYNMZFTE-UHFFFAOYSA-N (c-ethylsulfanylcarbonimidoyl)azanium;bromide Chemical compound Br.CCSC(N)=N SWXXKWPYNMZFTE-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 210000002683 foot Anatomy 0.000 description 7
- 208000004454 Hyperalgesia Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HUHDUJBASHFLIN-UHFFFAOYSA-N 4-bromo-1-chloro-2-propoxybenzene Chemical compound CCCOC1=CC(Br)=CC=C1Cl HUHDUJBASHFLIN-UHFFFAOYSA-N 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- AGYWDGVTLKNTBS-UHFFFAOYSA-N 4-bromo-1-chloro-2-fluorobenzene Chemical compound FC1=CC(Br)=CC=C1Cl AGYWDGVTLKNTBS-UHFFFAOYSA-N 0.000 description 1
- ICAKHSWCSZCVGZ-UHFFFAOYSA-N 6-(4-chloro-3-propoxyphenyl)-2-methyl-7-propan-2-yl-1h-quinazolin-4-one Chemical compound C1=C(Cl)C(OCCC)=CC(C=2C(=CC3=C(C(NC(C)=N3)=O)C=2)C(C)C)=C1 ICAKHSWCSZCVGZ-UHFFFAOYSA-N 0.000 description 1
- 0 COC(c1cc(*)c(*)cc1N)=O Chemical compound COC(c1cc(*)c(*)cc1N)=O 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003070 anti-hyperalgesia Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- LLRANSBEYQZKFY-UHFFFAOYSA-N dodecanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCCCC(O)=O LLRANSBEYQZKFY-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- RCOSUMRTSQULBK-UHFFFAOYSA-N sodium;propan-1-olate Chemical compound [Na+].CCC[O-] RCOSUMRTSQULBK-UHFFFAOYSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0223730.3A GB0223730D0 (en) | 2002-10-11 | 2002-10-11 | Organic compounds |
| PCT/EP2003/011276 WO2004033435A1 (en) | 2002-10-11 | 2003-10-10 | Quinazolinone derivatives useful as anti-hyperalgesic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006503875A JP2006503875A (ja) | 2006-02-02 |
| JP2006503875A5 true JP2006503875A5 (enExample) | 2006-11-24 |
| JP4571863B2 JP4571863B2 (ja) | 2010-10-27 |
Family
ID=9945785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004542493A Expired - Fee Related JP4571863B2 (ja) | 2002-10-11 | 2003-10-10 | 抗痛覚過敏剤として有用なキナゾリノン誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20060154942A1 (enExample) |
| EP (1) | EP1554257A1 (enExample) |
| JP (1) | JP4571863B2 (enExample) |
| CN (1) | CN100432059C (enExample) |
| AR (1) | AR041563A1 (enExample) |
| AU (1) | AU2003273989A1 (enExample) |
| BR (1) | BR0314557A (enExample) |
| CA (1) | CA2501529A1 (enExample) |
| GB (1) | GB0223730D0 (enExample) |
| PE (1) | PE20040736A1 (enExample) |
| TW (1) | TW200410695A (enExample) |
| WO (1) | WO2004033435A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0412769D0 (en) * | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
| US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| KR20060087386A (ko) | 2005-01-28 | 2006-08-02 | 주식회사 대웅제약 | 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물 |
| GB0507298D0 (en) | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
| GB0525068D0 (en) * | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525069D0 (en) * | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| CA2660957C (en) | 2006-08-23 | 2016-10-11 | Neurogen Corporation | 2-phenoxy pyrimidinone analogues |
| EP2079739A2 (en) * | 2006-10-04 | 2009-07-22 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists |
| JP5372138B2 (ja) | 2008-04-18 | 2013-12-18 | テウン ファーマシューティカル カンパニー，リミテッド | 新規ベンゾオキサジンベンズイミダゾール誘導体、これを含む薬学組成物およびこの用途 |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| JP2013518085A (ja) | 2010-02-01 | 2013-05-20 | ノバルティス アーゲー | ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体 |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
| EP2588197B1 (en) * | 2010-07-02 | 2014-11-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| KR101293384B1 (ko) | 2010-10-13 | 2013-08-05 | 주식회사 대웅제약 | 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도 |
| KR20140033377A (ko) | 2011-05-10 | 2014-03-18 | 길리애드 사이언시즈, 인코포레이티드 | 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물 |
| UY34094A (es) | 2011-05-27 | 2013-01-03 | Novartis Ag | Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina |
| NO3175985T3 (enExample) | 2011-07-01 | 2018-04-28 | ||
| UY34171A (es) | 2011-07-01 | 2013-01-31 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal iónico |
| CA2867043A1 (en) | 2012-05-03 | 2013-11-07 | Novartis Ag | L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
| US9884841B2 (en) | 2015-04-20 | 2018-02-06 | The Regents Of The University Of Michigan | Small molecule inhibitors of Mcl-1 and uses thereof |
| DE102022104759A1 (de) | 2022-02-28 | 2023-08-31 | SCi Kontor GmbH | Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE793737A (fr) * | 1972-01-06 | 1973-07-05 | Alkaline Batteries Ltd | Fermeture de trou de remplissage pour elements d'accumulateurs electriques |
| DE3041678A1 (de) * | 1979-11-15 | 1981-05-27 | Sandoz-Patent-GmbH, 7850 Lörrach | Ein 1-isopropyl-4-phenyl-2(1h)-chinazolinonderivat, dessen herstellung und verwendung |
| JPS56113769A (en) * | 1980-02-13 | 1981-09-07 | Sumitomo Chem Co Ltd | Novel 2 1h -quinazolinone derivative and its preparation |
| JPS5711970A (en) * | 1980-06-24 | 1982-01-21 | Tanabe Seiyaku Co Ltd | Quinazolinone compound and its preparation |
| JPS5714588A (en) * | 1980-07-02 | 1982-01-25 | Kanto Ishi Pharma Co Ltd | 1- tetrahydro-4-pyridyl -2-substituted-quinazolin-4-one derivative and its preparation |
| JPS57149277A (en) * | 1981-03-10 | 1982-09-14 | Taiho Yakuhin Kogyo Kk | Heterocyclic compound |
| DD206995A1 (de) * | 1982-01-20 | 1984-02-15 | Akad Wissenschaften Ddr | Verfahren zur herstellung von 9h-tetrazolo(5,1-b)chinazolin-9-onen |
| CS247557B1 (en) * | 1984-04-06 | 1987-01-15 | Ludmila Fisnerova | Esters of 3-(2-hydroxyethyl)-4(3h)-quinazolinone |
| US5290780A (en) * | 1991-01-30 | 1994-03-01 | American Cyanamid Co. | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
| US5284853A (en) * | 1993-04-23 | 1994-02-08 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
| US5294617A (en) * | 1993-04-23 | 1994-03-15 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
| EP0635263A3 (en) * | 1993-06-28 | 1995-09-27 | American Cyanamid Co | Angiotensin II antagonists (AII) as inhibitors of the growth of adipose tissue. |
| EP0760819B1 (en) * | 1994-05-24 | 2000-07-19 | F. Hoffmann-La Roche Ag | Tricyclic dicarbonyl derivatives |
| US5783577A (en) * | 1995-09-15 | 1998-07-21 | Trega Biosciences, Inc. | Synthesis of quinazolinone libraries and derivatives thereof |
| US5739330A (en) * | 1996-02-05 | 1998-04-14 | Hoechst Celanese Corporation | Process for preparing quinazolones |
| WO1997044041A1 (en) * | 1996-05-20 | 1997-11-27 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| WO1998018781A2 (en) * | 1996-10-28 | 1998-05-07 | Versicor, Inc. | Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents |
| AU4742101A (en) * | 2000-03-17 | 2001-10-03 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
-
2002
- 2002-10-11 GB GBGB0223730.3A patent/GB0223730D0/en not_active Ceased
-
2003
- 2003-10-06 TW TW092127685A patent/TW200410695A/zh unknown
- 2003-10-09 PE PE2003001026A patent/PE20040736A1/es not_active Application Discontinuation
- 2003-10-09 AR ARP030103674A patent/AR041563A1/es unknown
- 2003-10-10 EP EP03757959A patent/EP1554257A1/en not_active Withdrawn
- 2003-10-10 WO PCT/EP2003/011276 patent/WO2004033435A1/en not_active Ceased
- 2003-10-10 CA CA002501529A patent/CA2501529A1/en not_active Abandoned
- 2003-10-10 BR BR0314557-3A patent/BR0314557A/pt not_active IP Right Cessation
- 2003-10-10 JP JP2004542493A patent/JP4571863B2/ja not_active Expired - Fee Related
- 2003-10-10 AU AU2003273989A patent/AU2003273989A1/en not_active Abandoned
- 2003-10-10 US US10/530,897 patent/US20060154942A1/en not_active Abandoned
- 2003-10-10 CN CNB2003801029327A patent/CN100432059C/zh not_active Expired - Fee Related
-
2007
- 2007-12-04 US US11/950,079 patent/US20080293939A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006503875A5 (enExample) | ||
| JP5913400B2 (ja) | 核内受容体結合剤 | |
| US3974281A (en) | 5-Methyl-1-phenyl-2-(1H)-pyridone compositions and methods of use | |
| US4042699A (en) | Method for reducing serum glucose levels | |
| US4052509A (en) | Method for reducing serum uric acid levels | |
| JPH01139565A (ja) | フェネタノールアミン誘導体 | |
| US3949089A (en) | Substituted guanidine compounds as antifibrillatory agents | |
| DE3239172A1 (de) | Salze von sulfodehydroabietinsaeure und arzneimittel, welche diese enthalten | |
| JP2010514696A (ja) | 心血管症状の低減 | |
| KR20150065873A (ko) | 케타민 유도체 | |
| JPH07501313A (ja) | キノロン誘導体 | |
| JP5084736B2 (ja) | 肺高血圧を処置するためのジアリールウレア | |
| JP3131693B2 (ja) | 眼疾患を処置するための５―メチル―イソオキサゾール―４―カルボン酸アニリド類または２―ヒドロキシエチリデン―シアノ酢酸アニリド類含有医薬組成物 | |
| WO2009122187A2 (en) | Pharmaceutical composition | |
| BR112020024807A2 (pt) | ácido ascórbico e compostos de quinona em combinação com um agente antiparasítico para tratar uma doença parasítica | |
| WO2006118329A1 (ja) | 安定な乳化組成物 | |
| US20230330116A1 (en) | Materials and methods for suppressing and/or treating bone related diseases and symptoms | |
| WO2002045750A1 (en) | Combination drugs | |
| US5496850A (en) | Antimetastasis agent of malignant tumors | |
| CN101374807A (zh) | 用于抑制bcl蛋白与结合配偶体的相互作用的化合物和方法 | |
| EA007952B1 (ru) | Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии | |
| JP2665357B2 (ja) | 心不全治療用医薬組成物 | |
| EP0623346B1 (en) | Inhibitor for metastasis of malignant tumor | |
| JP3090211B2 (ja) | 第４級ｎ−ベンジル−ｎ−｛２−〔２−（（１ｓ，５ｓ）−６，６−ジメチルビシクロ〔３．１．１〕−ヘプト−２−イル）エトキシ〕エチル｝モルホリニウム塩を含有する胃保護作用を有する製薬学的調剤およびその製造法 | |
| JPS6219405B2 (enExample) |